Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $58.9 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) rose 134.32% to $58.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.9 million, marking a year-over-year increase of 134.32%. This contributed to the annual value of $58.9 million for FY2025, which is 134.32% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Shares Outstanding (Weighted Average) of $58.9 million as of Q4 2025, which was up 134.32% from $59.1 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $59.1 million in Q3 2025 and a low of $55.1 million during Q1 2021
  • Its 5-year average for Shares Outstanding (Weighted Average) is $57.2 million, with a median of $57.4 million in 2023.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) surged by 248.94% in 2021 and then soared by 129.16% in 2024.
  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $55.5 million in 2021, then rose by 1.64% to $56.5 million in 2022, then increased by 1.63% to $57.4 million in 2023, then grew by 1.34% to $58.1 million in 2024, then rose by 1.34% to $58.9 million in 2025.
  • Its last three reported values are $58.9 million in Q4 2025, $59.1 million for Q3 2025, and $59.0 million during Q2 2025.